EIF2AK4 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1992515	0.51	19/20
SCHEMBL1992517	0.51	19/20
SCHEMBL376422	0.48	8/20
SCHEMBL376423	0.48	8/20
SCHEMBL1693880	0.34	8/20
SCHEMBL1694683	0.34	8/20
SCHEMBL1693647	0.44	7/20
SCHEMBL1693651	0.44	7/20
SCHEMBL1992451	0.44	7/20
SCHEMBL1992453	0.44	7/20
SCHEMBL1355821	0.62	5/20
SCHEMBL1655180	0.44	5/20
SCHEMBL1356007	0.67	4/20
SCHEMBL1356186	0.67	4/20
SCHEMBL1355771	0.64	4/20
SCHEMBL1356855	0.64	4/20
SCHEMBL1355725	0.64	4/20
SCHEMBL1355988	0.62	4/20
SCHEMBL1355858	0.61	4/20
SCHEMBL1355980	0.61	4/20

Clinical trials — most relevant to EIF2AK4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Counteracting Deleterious Metabolic Glucocorticoid Effects With Metformin	PHASE4	COMPLETED
Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes	PHASE4	UNKNOWN
Alpha Ketoglutarate Enhances Geroprotection In Surgery (AEGIS)	PHASE4	RECRUITING
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Strategies to Reduce Organic Muscle Atrophy in the Intensive Care Unit	PHASE2/PHASE3	WITHDRAWN
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Targeting Endoplasmic Reticulum Stress in Human Hypertension	PHASE1/PHASE2	RECRUITING
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients	PHASE1/PHASE2	COMPLETED
Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery	PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer	PHASE1	COMPLETED
PBA Use for Treatment of ATF6-/- Patients	EARLY_PHASE1	SUSPENDED
Quantification of GADD34 Expression in RA	nan	COMPLETED
Intermittent Fasting for Pancreatitis	nan	NOT_YET_RECRUITING
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy	nan	RECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Predisposition Genes in Monogenic Diabetes (DIAMONO)	nan	COMPLETED
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases	nan	NOT_YET_RECRUITING
Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory	nan	COMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
Impact of Mutations in Aminoacyl tRNA Synthetases on Protein Translation and Cellular Stress	nan	WITHDRAWN
The Effects of Whey vs. Collagen on MPS	nan	COMPLETED
Muscle Regrowth During Physical Rehabilitation and Amino Acid Supplementation	nan	COMPLETED
Effects of a Multiple Sclerosis Relapse Therapy on Offspring Neurocognitive Development and Behaviour	nan	UNKNOWN
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation	nan	COMPLETED
Testing of Micellar Casein, Blended Micellar Casein and Native Whey	nan	COMPLETED
Effect of Protein on Endoplasmic Reticulum Stress	nan	NOT_YET_RECRUITING
Exercise Effects on Cardiometabolic Health and Sestrin-2 in Hypertensive Obese Women	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a EIF2AK4 binder may also engage these)

Protein	Name	Similarity
D4A7V9	—	1.000	D4A7V9 →
Q9QZ05	—	1.000	Q9QZ05 →
Q9Z2R9	—	0.989	Q9Z2R9 →
Q0P5I2	—	0.989	Q0P5I2 →
P97874	—	0.988	P97874 →
Q99KY4	—	0.987	Q99KY4 →
NEK11	Serine/threonine-protein kinase Nek11	0.987	landscape →
Q4R8E0	—	0.987	Q4R8E0 →
E1BTE1	—	0.987	E1BTE1 →
A4QNA8	—	0.987	A4QNA8 →
Q9D684	—	0.987	Q9D684 →
Q8K1R7	—	0.987	Q8K1R7 →
O70551	—	0.987	O70551 →
Q8C0M0	—	0.986	Q8C0M0 →
Q69Z98	—	0.986	Q69Z98 →
BRSK2	Serine/threonine-protein kinase BRSK2	0.986	landscape →
Q6NVF4	—	0.986	Q6NVF4 →
Q8C0Q4	—	0.986	Q8C0Q4 →
Q68DX3	—	0.986	Q68DX3 →
Q8S8Y8	—	0.986	Q8S8Y8 →
P0C218	—	0.986	P0C218 →
Q6YY75	—	0.986	Q6YY75 →
PIK3C2B	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	0.986	landscape →
Q9EQY0	—	0.985	Q9EQY0 →
P33279	—	0.985	P33279 →
Q8WNU8	—	0.985	Q8WNU8 →
Q5F479	—	0.985	Q5F479 →
GAK	Cyclin-G-associated kinase	0.985	landscape →
Q61084	—	0.985	Q61084 →
Q5RJI5	—	0.985	Q5RJI5 →